Allogene Therapeutics Files 8-K
Ticker: ALLO · Form: 8-K · Filed: Apr 13, 2026
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: ALLO
TL;DR
ALLO filed an 8-K on 4/13/26, check for updates.
AI Summary
Allogene Therapeutics, Inc. filed an 8-K on April 13, 2026, reporting other events. The filing does not contain specific financial figures or new material agreements, but rather serves as a notification of events.
Why It Matters
This 8-K filing indicates that Allogene Therapeutics has reported an event, which could be significant for investors monitoring the company's ongoing activities and disclosures.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose specific material financial information or significant corporate actions that would immediately alter risk.
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Filer of the 8-K
- 0001737287 (company) — CIK number for Allogene Therapeutics, Inc.
- 2026-04-13 (date) — Filing date of the 8-K
FAQ
What is the primary purpose of this 8-K filing by Allogene Therapeutics?
The primary purpose of this 8-K filing, dated April 13, 2026, is to report 'Other Events' as per Item 8.01.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on April 13, 2026, at 16:09:04.
What is the CIK number for Allogene Therapeutics, Inc.?
The CIK number for Allogene Therapeutics, Inc. is 0001737287.
What is the business address and phone number listed for Allogene Therapeutics?
The business address listed is 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080, and the phone number is (650) 457-2700.
What SIC code is associated with Allogene Therapeutics, Inc.?
The SIC code associated with Allogene Therapeutics, Inc. is 2836, which pertains to Biological Products, (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 13, 2026 regarding Allogene Therapeutics, Inc. (ALLO).